load more
Brooklyn ImmunoTherapeutics Inc is a clinical stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-07-09
REV
Q1 2021Est.ActualSurprise
EPS-0.290
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
BTXBrooklyn4.37%

Brooklyn Frequently Asked Questions

Q

How do I buy Brooklyn (BTX) stock?

A

You can purchase shares of Brooklyn (AMEX: BTX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Brooklyn's (BTX) competitors?

A

There are no as such competitors for Brooklyn.

Q

What is the target price for Brooklyn (BTX) stock?

A

The latest price target for Brooklyn (AMEX: BTX) was reported by Raymond James on June 14, 2019. The analyst firm set a price target for 0.00 expecting BTX to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Brooklyn (BTX)?

A

The stock price for Brooklyn (AMEX: BTX) is $15.5612 last updated Wed Jun 16 2021 19:59:59 GMT+0000 (Coordinated Universal Time).

Q

Does Brooklyn (BTX) pay a dividend?

A

There are no upcoming dividends for Brooklyn.

Q

When is Brooklyn (AMEX:BTX) reporting earnings?

A
Brooklyn’s Q2 earnings are confirmed for after-market on July 9, 2021.
Q

Is Brooklyn (BTX) going to split?

A

There is no upcoming split for Brooklyn.

Q

What sector and industry does Brooklyn (BTX) operate in?

A

Brooklyn is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the AMEX.